Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-PSFA is a novel dual-targeting radiopharmaceutical used for positron emission tomography (PET) imaging. This innovative diagnostic radiopharmaceutical is designed for imaging PSMA/FAP positive diseases, particularly in oncology applications. The dual-target nature of 68Ga-PSFA enhances its detection capabilities compared to single-target agents like 68Ga-PSMA-11. Clinical studies have shown that 68Ga-PSFA-01 PET/CT demonstrated higher detection rates and visual assessment efficacy compared to 68Ga-PSMA-11 PET/CT in prostate cancer patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 68Ga-PSFA.